Morpholine → HCID 178488349, compound
Reaction equation
Cl[CH2:2][C:3]([NH:5][C:6]1[CH:27]=[CH:26][C:9]2[N:10]=[C:11]([NH:14][CH:15]3[C:19]4[C:20]([O:24][CH3:25])=[CH:21][CH:22]=[CH:23][C:18]=4[O:17][CH2:16]3)[O:12][CH2:13][C:8]=2[CH:7]=1)=[O:4].[NH:28]1[CH2:33][CH2:32][O:31][CH2:30][CH2:29]1>>[CH3:25][O:24][C:20]1[C:19]2[CH:15]([NH:14][C:11]3[O:12][CH2:13][C:8]4[CH:7]=[C:6]([NH:5][C:3](=[O:4])[CH2:2][N:28]5[CH2:33][CH2:32][O:31][CH2:30][CH2:29]5)[CH:27]=[CH:26][C:9]=4[N:10]=3)[CH2:16][O:17][C:18]=2[CH:23]=[CH:22][CH:21]=1Participants
3
Procedure
Prepared from rac-2-chloro-N-[2-(4-methoxy-2,3-dihydro-benzofuran-3-ylamino)-4H-benzo[d][1,3]oxazin-6-yl]-acetamide (Example 8) (50 mg, 0.129 mmol) and morpholine (225 ul, 2.578 mmol) according to the procedure described for Example 3 step B (here the reaction was sonicated for 2 min, which already lead to complete conversion). Obtained the title compound as a white solid (20 mg, 35%), MS (ISP) m/e=439.3 [(M+H)+].
Workup
- customwas sonicated for 2 min
Sources & evidence
- ORD record
- ord-145a4f0bd73844bcaba08eb169b58538
- Source dataset
- uspto-grants-2012_04
- Patent number
- US08163740B2
Reaction notes
Loading…